PDCPentadecanoylcarnitine
The carnitine ester of a dietary fatty acid, described in 2022 as a full agonist of CB1 and CB2 at micromolar concentrations.
C₂₂H₄₃NO₄
CID 123132011
- Family
- Endocannabinoid or related mediatorPutative
- Molar mass
- 385.60 g/mol
Updated on
In plain terms
Pentadecanoylcarnitine comes from a fatty acid supplied by the diet, mainly by dairy fat. Its established role is to help fats enter the mitochondria. A 2022 screen additionally found activity at the receptors of the endocannabinoid system, at high concentrations and with no independent confirmation so far.
Receptors and activity
Target network
- Activates
The lower the cited value, the closer the target sits to PDC: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of PDC.
CB1CB1 found in 7 regions of the body
- Basal gangliadenseMost dense in basal ganglia outflow nuclei1
- CerebellumdenseVery dense in the cerebellum1
- HippocampusdenseVery high concentrations in the hippocampus2
- AmygdaladenseHigh concentrations in the amygdala2
- CortexpresentPresent throughout the neocortex2
- Adipose tissuepresentExpressed in adipose tissue3
- GutpresentColonic epithelium, smooth muscle and plexus4
Map sources
- Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
- Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
Cited values
- CB1AgonistEC50 = 3.7 µM · human24 out of 100
Venn-Watson et al. 2022, Sci Rep (new tab) · cell-based target assay; full agonist, maximal effect 111% of the positive control
- CB2AgonistEC50 = 3.2 µM · human25 out of 100
Venn-Watson et al. 2022, Sci Rep (new tab) · cell-based target assay; full agonist, maximal effect 106% of the positive control
- 5-HT1AAgonistno measured value cited
Agonist activity noted in the same screen, with no value published in the abstract; also a 5-HT1B agonist and an antagonist of the histamine H1 and H2 receptors (Venn-Watson 2022)
Pharmacology
Pentadecanoylcarnitine is the carnitine ester of pentadecanoic acid, a dietary saturated fifteen-carbon fatty acid supplied mainly by dairy fat and which the body does not synthesise in sufficient quantity (Ciesielski 2024). Its established function is metabolic: acylcarnitines are the intermediates of fatty acid oxidation, and this esterification is the form in which fatty acids cross the inner mitochondrial membrane (Giesbertz 2015). Venn-Watson and colleagues attributed a second, signalling function to it in 2022, following a screen of 148 biomarkers across twelve primary human cell systems and 78 target assays. The compound behaved there as a full agonist of both cannabinoid receptors, with median effective concentrations of 3.7 µM at CB1 and 3.2 µM at CB2 and maximum effects slightly above those of the positive control, which led the authors to present it as the second full-acting endocannabinoid identified. The same work found agonist activity at the 5-HT1A and 5-HT1B receptors, antagonist activity at the H1 and H2 receptors, and dose-dependent decreases in interleukin-1 alpha, ITAC, MCP-1 and IP-10 in five cell systems. Three reservations attach to these results: the effective concentrations are in the micromolar range, far above those of the reference endocannabinoid ligands; the authors declare interests with the companies that commercialise odd-chain fatty acids; and no independent team has published a replication. This is why the classification places it among the putative endocannabinoids rather than the established ones.
Key sources.
- Venn-Watson et al. 2022, Sci Rep: pentadecanoylcarnitine, an endocannabinoid with pleiotropic activities (EC50 3.7 and 3.2 µM at CB1 and CB2) (new tab)PMID 35999445
- Giesbertz et al. 2015, J Lipid Res: LC-MS/MS method for quantifying isomeric and odd-chain acylcarnitines (new tab)PMID 26239049
- Santaren et al. 2014, Am J Clin Nutr: serum 15:0, a short-term marker of dairy consumption (new tab)PMID 25411288
- Ciesielski et al. 2024, Biochimie: pentadecanoic acid and its contested essentiality (mini-review) (new tab)PMID 39395658
- PubChem CID 123132011, pentadecanoylcarnitine (new tab)
History
- Source
- An endogenous compound: it is the carnitine metabolite of pentadecanoic acid, a saturated fifteen-carbon fatty acid that the body does not synthesise in sufficient quantity and which comes from the diet, mainly from dairy fat (Ciesielski 2024); serum 15:0 is in fact used as a short-term marker of dairy product consumption (Santaren 2014). Its presence in the body therefore depends on that dietary intake.
Biosynthetic pathway
In vivo
The molecule is neither an N-acylethanolamine nor a monoacylglycerol, unlike the classical endocannabinoids: it is a carnitine ester. It is formed by transfer of pentadecanoic acid, activated as a coenzyme A thioester, onto the hydroxyl function of L-carnitine, a reaction catalysed by the carnitine acyltransferases. Acylcarnitines are the intermediates of fatty acid and amino acid oxidation (Giesbertz 2015): this esterification is the step that allows fatty acids to cross the inner mitochondrial membrane, upstream of their oxidation. The compound is therefore primarily an intermediate of fatty acid transport, the signalling activity attributed to it being a second function.
Legal framework
- European Union
Not controlled: the compound is covered by no European control decision and by no schedule of the 1961 and 1971 United Nations conventions. Any nutritional or health claim about the fatty acid it derives from would fall to assessment by the European Food Safety Authority, which has not ruled on this metabolite.
- France
An endogenous substance, listed neither as a narcotic nor as a psychotropic substance (orders of 22 February 1990), and foreign to the benzo[c]chromene family covered by the ANSM decisions of June 2024. The pentadecanoic acid it comes from is a normal dietary constituent. No particular status attaches to the metabolite itself, which is not marketed as such in France.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
Endocannabinoid or related mediator › Putative
- Verification
Every fact on this entry was checked against its primary sources on 20 October 2026.
- Wikipedia (English)
Pentadecanoylcarnitine (new tab)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Venn-Watson et al. 2022, Sci Rep: pentadecanoylcarnitine, an endocannabinoid with pleiotropic activities (EC50 3.7 and 3.2 µM at CB1 and CB2) (new tab)PMID 35999445
- Giesbertz et al. 2015, J Lipid Res: LC-MS/MS method for quantifying isomeric and odd-chain acylcarnitines (new tab)PMID 26239049
- Santaren et al. 2014, Am J Clin Nutr: serum 15:0, a short-term marker of dairy consumption (new tab)PMID 25411288
- Ciesielski et al. 2024, Biochimie: pentadecanoic acid and its contested essentiality (mini-review) (new tab)PMID 39395658
- PubChem CID 123132011, pentadecanoylcarnitine (new tab)
Identifiers
Names
- Common name
- Pentadecanoylcarnitine
- IUPAC name
- 3-pentadecanoyloxy-4-(trimethylazaniumyl)butanoate
- Other names
- C15:0 carnitine
Identifiers
- Formula
- C₂₂H₄₃NO₄
- PubChem CID
- 123132011(new tab)
- InChIKey
- MDDWQHVKSHTZTD-UHFFFAOYSA-N
- SMILES
- CCCCCCCCCCCCCCC(=
O) OC(CC(= O) [O-] ) C[N+] (C) (C) C
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.